Related Experiment Video

Updated: Apr 23, 2026

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods
07:49

Characterize Disease-related Mutants of RAF Family Kinases by Using a Set of Practical and Feasible Methods

Published on: July 17, 2019

5.7K

Molecular pathways: targeting RAC-p21-activated serine-threonine kinase signaling in RAS-driven cancers

Nicole M Baker1, Hoi Yee Chow2, Jonathan Chernoff2

  • 1Department of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina. Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina.

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|September 17, 2014
PubMed

Insights

Targeting Ras-driven cancers requires new approaches. This review explores the therapeutic potential of Rac and p21-activated kinases (PAK) as novel targets in these deadly diseases.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Ras-driven cancers are a leading cause of cancer mortality, necessitating novel therapeutic strategies.
  • Current therapies targeting Ras effector pathways like ERK and PI3K have shown limited efficacy in RAS-mutant cancers.
  • This limitation is partly due to the involvement of alternative effectors, including Rac and p21-activated kinases (PAK), in cancer progression.

Purpose of the Study:

  • To review the role of Rac and group I PAK proteins in the development and progression of Ras-driven cancers.
  • To evaluate the therapeutic potential of targeting Rac and PAK pathways as a novel strategy for treating these cancers.

Main Methods:

  • Literature review of studies investigating Ras signaling pathways.
  • Analysis of the involvement of Rac and PAK proteins in cancer cell survival, motility, and proliferation.
  • Examination of existing and potential therapeutic interventions targeting Rac and PAK.

Main Results:

  • Mutant Ras proteins drive cancer through various effector pathways, including Rac and PAK.
  • PAK proteins are implicated in critical cellular processes that promote cancer growth.
  • Targeting Rac and PAK may offer a promising therapeutic avenue for Ras-mutant cancers.

Conclusions:

  • Rac and group I PAK proteins represent viable and underexplored therapeutic targets in Ras-driven cancers.
  • Further research into the specific roles and inhibition of these pathways is warranted.
  • Developing inhibitors for Rac and PAK could lead to more effective treatments for deadly Ras-mutant cancers.

More Related Videos

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer06:51

Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

Published on: July 21, 2018

18.9K
Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans08:12

Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans

Published on: October 5, 2020

2.3K

Related Concept Videos

The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
5.7K
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
7.3K
Small GTPases - Ras and Rho01:24

Small GTPases - Ras and Rho

Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity:
4.4K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.6K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

1.5K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.1K